What Is Sinovac Biotech, Ltd. (SVA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, our multi-model framework produces a cautiously optimistic read on Sinovac Biotech, Ltd. at $6.47. With an estimated intrinsic value of $14.02 and 3 of 5 models pointing higher, the average implied return is +116.8%. The most optimistic model, Bayesian DCF, places fair value at $29.51 (+356.1%), while Regime Cross — the most conservative — estimates $4.04 (-37.5%). This +393.6% gap reflects genuine analytical uncertainty about Sinovac Biotech, Ltd.'s intrinsic worth.
What Do the Models Say About SVA?
5 of 13 models are currently active for SVA. Of these, 3 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates SVA's intrinsic value at $29.51, implying +356.1% upside from the current price. See which stocks rank higher →
How Does SVA Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, SVA ranks #403 by Quality of Company score. CirclFi's QOC score of 2.5/10 evaluates 32 fundamental signals. A score of 2.5 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Sinovac Biotech, Ltd.'s positioning within the Pharmaceutical Preparations segment means that R&D productivity ratio plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.
Is SVA a Value Trap?
The Value Trap algorithm is not active for SVA. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
5 of 13 models are active for Sinovac Biotech, Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Sinovac Biotech, Ltd. scores 2.5 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +393.6% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every SVA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across SVA's 5 active models, average confidence is 18%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad